

Product Data Sheet

Product Name: Ganaplacide hydrochloride

Cat. No.: GC60864

Chemical Properties

Cas. No. 2751586-94-2

SMILES FC(C=C1)=CC=C1C2=C(N3C(C(C)(N(C(CN)=O)CC3)C)=N2)NC4=CC=C(F)C=C4.[H]C
I


Formula $C_{22}H_{24}ClF_2N_5O$ M.Wt 447.91

Solubility DMSO: 100 mg/mL (223.26 mM) Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

Ganaplacide (KAF156) hydrochloride is a first-in-class, orally active imidazolopiperazine antimalarial agent. Ganaplacide hydrochloride is active against a broad range of Plasmodium species, including drug-resistant parasites. Ganaplacide hydrochloride is parasitocidal against both asexual and sexual blood stages as well as the liver stages of the parasite[1][2].

Ganaplacide (KAF156) hydrochloride shows blood schizonticidal activity with 50% inhibitory

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

concentrations of 6 to 17.4 nM against *P. falciparum* drug-sensitive and drug-resistant strains[1].

KAF156 displays cidal activity against mature *Plasmodium falciparum* gametocytes and thus blocks parasite transmission to *Anopheles* mosquitoes[1]. Ganaplacide (KAF156) hydrochloride (1-15 mg/kg; p.o.) is fully protective in a causal prophylactic mouse model of malaria[1]. Animal Model: Mice (causal prophylactic rodent malaria model)[1]

[1]. Kuhen KL, et al. KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission. *Antimicrob Agents Chemother.* 2014;58(9):5060-5067. [2]. Leong FJ, et al. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. *Antimicrob Agents Chemother.* 2014;58(11):6437-6443.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA